1. Chronic myeloid leukemia (CML) is a blood cancer in which a single genetic accident in a bone marrow stem cell switches on uncontrolled growth. In more than 95% of cases this accident is a swap of material between chromosomes 9 and 22, written t(9;22) and known as the Philadelphia chromosome. What is the direct molecular consequence of this chromosome swap that makes it the cause of the disease?
A) It deletes a tumor-suppressor gene, removing the normal brake on cell division
B) It silences the gene for an enzyme that repairs damaged DNA, allowing mutations to accumulate
C) It fuses two genes (BCR and ABL1) together, producing an abnormal, always-on tyrosine kinase enzyme
D) It triples the number of copies of a normal growth-factor receptor gene
E) It inserts a viral gene that forces the cell into continuous division
ANSWER: C
Rationale:
Option C is correct. The t(9;22) translocation joins the breakpoint cluster region (BCR) gene on chromosome 22 to the Abelson (ABL1) gene on chromosome 9. The resulting BCR-ABL1 fusion gene encodes a tyrosine kinase — an enzyme that attaches phosphate groups to other proteins to switch them on. Normal ABL1 kinase is tightly regulated and turns itself off; the BCR-ABL1 fusion protein has lost that off-switch and is constitutively active (permanently turned on). This continuous signaling drives the unregulated proliferation, resistance to programmed cell death, and genomic instability that define CML. Because this single abnormal enzyme sits at the root of the disease, it is an ideal drug target — the conceptual foundation for every drug in this module.
Option A: Option A is incorrect. CML is driven by a gain-of-function fusion oncogene, not by deletion of a tumor-suppressor gene. The Philadelphia chromosome creates a new abnormal protein rather than removing a normal brake.
Option B: Option B is incorrect. The translocation does not silence a DNA-repair enzyme. While genomic instability is a downstream feature of advanced CML, the initiating event is creation of the active BCR-ABL1 kinase, not loss of DNA repair.
Option D: Option D is incorrect. Gene amplification (extra copies) of a growth-factor receptor is a mechanism seen in some other cancers, but the Philadelphia chromosome is a translocation that fuses two genes, not an amplification.
Option E: Option E is incorrect. No virus is involved. The Philadelphia chromosome is an acquired translocation within the patient's own DNA, not an inserted viral gene.
2. Imatinib was the first drug of its kind approved for cancer and remains the classic example of targeted therapy. It works by sitting in the pocket of the BCR-ABL1 enzyme where ATP (adenosine triphosphate, the molecule that supplies the phosphate the enzyme transfers) would normally bind. Based on this mechanism, why does imatinib stop the cancer cell's growth signal?
A) By occupying the ATP-binding pocket, it blocks the kinase from transferring phosphate to its target proteins, shutting off the downstream growth signal
B) It binds DNA directly and prevents the cancer cell from copying its genome
C) It stimulates the immune system to recognize and destroy BCR-ABL1-positive cells
D) It crosslinks proteins on the cell surface so the cell can no longer divide
E) It blocks the cell's ability to take up glucose, starving it of energy
ANSWER: A
Rationale:
Option A is correct. A tyrosine kinase works by grabbing ATP and transferring its terminal phosphate group onto target proteins, switching those proteins on. Imatinib is an ATP-competitive inhibitor: it fits into the same ATP-binding pocket of the BCR-ABL1 kinase (it binds the inactive, DFG-out conformation of the kinase domain) so that ATP can no longer dock there. With no phosphate transfer, the downstream proliferation and survival signals are silenced and the leukemic cell loses its growth drive. This is the core concept of small-molecule kinase inhibition that every drug in this module shares.
Option B: Option B is incorrect. Imatinib does not bind DNA. Direct DNA binding describes classic cytotoxic chemotherapy (for example alkylating agents), not a targeted kinase inhibitor.
Option C: Option C is incorrect. Imatinib is not an immunotherapy; it does not work by activating immune cells. It directly inhibits an intracellular enzyme.
Option D: Option D is incorrect. Imatinib does not crosslink surface proteins. It enters the cell and occupies the kinase's ATP pocket.
Option E: Option E is incorrect. Imatinib does not act by blocking glucose uptake. Its selectivity comes specifically from binding the BCR-ABL1 kinase ATP site.
3. Throughout this module the drugs are referred to as TKIs. A student reading a chart sees a patient is taking a "TKI" for lung cancer. What does this abbreviation stand for, and what does that tell the clinician about how the drug works?
A) Tumor kinetic index — a laboratory score that tracks how fast a tumor is growing
B) Tyrosine kinase inhibitor — a drug that blocks a signaling enzyme (a tyrosine kinase) that the cancer depends on for growth
C) Targeted killing immunoconjugate — an antibody chemically linked to a toxin
D) Transmembrane channel inhibitor — a drug that blocks ion movement across the cell membrane
E) Tissue kinase activator — a drug that turns on enzymes to promote normal cell repair
ANSWER: B
Rationale:
Option B is correct. TKI stands for tyrosine kinase inhibitor. A tyrosine kinase is an enzyme that switches other proteins on by adding phosphate to their tyrosine amino acids; many cancers are driven by a tyrosine kinase that is abnormally or permanently active. A TKI is a drug that blocks that enzyme, cutting off the growth and survival signal the cancer cell relies on. Recognizing the term immediately tells the clinician the drug is a targeted oral agent acting on a specific signaling enzyme — and that drug interactions, resistance mutations, and on-target side effects (covered later in this module) are the relevant concerns.
Option A: Option A is incorrect. There is no drug class called "tumor kinetic index"; this invents a laboratory term, not a mechanism of action.
Option C: Option C is incorrect. An antibody linked to a toxin is an antibody-drug conjugate, a different class entirely. A TKI is a small molecule, not an immunoconjugate.
Option D: Option D is incorrect. TKIs do not block ion channels. The "K" stands for kinase (an enzyme), not a potassium or other ion channel.
Option E: Option E is incorrect. A TKI inhibits a kinase rather than activating one, and it targets cancer-driving signaling rather than promoting normal repair. The word "inhibitor" is the key.
4. A patient is diagnosed with non-small cell lung cancer (NSCLC, the most common type of lung cancer), and molecular testing of the tumor reports an "activating EGFR mutation." EGFR (epidermal growth factor receptor) is a surface receptor that, when switched on, drives cell growth. Why does finding this specific mutation matter for choosing treatment?
A) It means the tumor will not respond to any drug therapy and only surgery can help
B) It indicates the cancer was caused by smoking and predicts a poor response to all treatment
C) It shows the tumor lacks any treatment target, so standard chemotherapy is the only option
D) It identifies a tumor whose growth depends on the mutated EGFR enzyme, making it highly responsive to an EGFR-targeted TKI
E) It signals that the tumor is benign and unlikely to spread
ANSWER: D
Rationale:
Option D is correct. An "activating" EGFR mutation (most commonly an exon 19 deletion, abbreviated del19, or the L858R point mutation) locks the EGFR kinase in the on position, so the cancer cell becomes dependent on that single overactive enzyme to keep growing — a state called oncogene addiction. A drug that specifically shuts off EGFR (an EGFR-targeted TKI) therefore produces response rates and progression-free survival far superior to standard chemotherapy in these patients. This is exactly why molecular testing is performed before treatment: the mutation predicts who will benefit from targeted therapy.
Option A: Option A is incorrect. The opposite is true — the mutation predicts an excellent response to targeted drug therapy, not a need for surgery alone.
Option B: Option B is incorrect. EGFR-mutant NSCLC actually occurs more often in never-smokers or light smokers, and the mutation predicts a good (not poor) response to EGFR TKIs.
Option C: Option C is incorrect. The mutation defines a treatment target rather than the absence of one; it is the reason to choose a targeted TKI over chemotherapy.
Option E: Option E is incorrect. The tumor is malignant. The mutation guides therapy selection; it does not indicate a benign lesion.
5. Another patient with non-small cell lung cancer has tumor testing that reports an "ALK rearrangement." ALK (anaplastic lymphoma kinase) is a tyrosine kinase that is normally silent in lung tissue. In this tumor, a piece of one gene has become fused to the ALK gene (most often the EML4-ALK fusion). What is the significance of this finding?
A) It means the tumor is resistant to targeted therapy and behaves like small cell lung cancer
B) It indicates the patient also has an EGFR mutation, since the two usually occur together
C) It shows the tumor is driven by inflammation rather than by a specific enzyme
D) It rules out the possibility of brain metastasis
E) The fusion creates a constitutively active ALK kinase that drives the cancer, making it treatable with an ALK-targeted TKI
ANSWER: E
Rationale:
Option E is correct. The fusion gene (EML4-ALK is the most common) produces a fusion protein in which the ALK kinase is constitutively active — permanently switched on — and this single overactive enzyme drives the cancer's growth. As with EGFR mutations, this dependence makes the tumor highly responsive to a drug that specifically blocks ALK (an ALK-targeted TKI). ALK rearrangements occur in roughly 3–5% of NSCLC, more often in younger patients and never- or light-smokers with adenocarcinoma. Identifying the fusion is what makes ALK-directed targeted therapy possible.
Option A: Option A is incorrect. An ALK rearrangement predicts sensitivity to ALK-targeted therapy, not resistance, and is unrelated to small cell lung cancer.
Option B: Option B is incorrect. ALK and EGFR alterations are essentially mutually exclusive — they do not occur together in the same tumor — so finding one argues against the other.
Option C: Option C is incorrect. The cancer is driven by a specific overactive enzyme (the ALK fusion kinase), not by inflammation.
Option D: Option D is incorrect. ALK-positive NSCLC actually has a high propensity for brain metastasis; the rearrangement does not rule it out and in fact makes CNS penetration of therapy an important concern.
6. A patient with CML has been doing well on imatinib for two years, but now the leukemia is returning. Testing of the BCR-ABL1 enzyme reveals a "gatekeeper" mutation called T315I, in which the amino acid at position 315 has changed. The gatekeeper residue sits at the entrance to the ATP-binding pocket where the drug must dock. Why does this single mutation cause resistance?
A) The substituted amino acid blocks the drug from fitting into the ATP-binding pocket, so the drug can no longer reach its target — while the enzyme stays fully active
B) The mutation destroys the enzyme, so there is no longer any target for the drug to bind
C) The mutation makes the cell pump the drug out faster, lowering the drug level inside the cell
D) The mutation switches the cancer's growth to a completely different, non-kinase pathway
E) The mutation causes the liver to break down the drug more quickly
ANSWER: A
Rationale:
Option A is correct. The gatekeeper residue controls access to the ATP-binding pocket. The T315I substitution (threonine replaced by isoleucine at position 315) removes a hydrogen bond the drug needs and adds bulk that physically obstructs the pocket. The drug can no longer dock, yet the kinase itself remains fully active and keeps driving the leukemia. This is the conceptual definition of a resistance mutation at the drug-binding site: the target survives but the drug is locked out. T315I is the classic example because it defeats imatinib and the second-generation TKIs alike.
Option B: Option B is incorrect. The mutation does not destroy the enzyme — the kinase stays active. If the target were gone, there would be no driver for the relapsing leukemia.
Option C: Option C is incorrect. T315I changes the drug-binding pocket itself; it is not a drug-efflux (pump) mechanism. Increased efflux is a separate, distinct resistance route.
Option D: Option D is incorrect. The leukemia is still driven by the same BCR-ABL1 kinase; the mutation alters drug binding rather than switching to a non-kinase pathway.
Option E: Option E is incorrect. T315I is a change in the target protein, not a change in how fast the liver metabolizes the drug. Accelerated hepatic metabolism is a pharmacokinetic interaction, not a binding-site mutation.
7. A patient started on an EGFR-targeted TKI for lung cancer develops an acne-like (papulopustular) rash on the face, scalp, and upper chest within the first two weeks. EGFR is normally active not only in the tumor but also in the skin. What best explains why this rash is the most common side effect of this drug class?
A) The rash is an allergic reaction and means the drug must be stopped permanently
B) The rash is an infection caused by the drug suppressing the immune system
C) The drug blocks EGFR in normal skin cells just as it does in the tumor, and this on-target effect on the skin produces the characteristic rash
D) The rash reflects the drug being deposited directly in the skin as crystals
E) The rash is caused by the drug raising blood sugar, which damages the skin
ANSWER: C
Rationale:
Option C is correct. EGFR is essential for normal growth and maintenance of the skin's basal epidermal layer. An EGFR TKI cannot tell the difference between tumor EGFR and skin EGFR, so blocking the receptor in the skin disrupts normal keratinocyte function and produces the acneiform (papulopustular) rash seen in 50–80% of patients. This is the textbook example of an on-target, off-tumor toxicity — the side effect arises from the drug doing exactly what it is designed to do, just in healthy tissue. Notably, the rash typically appears in the first two weeks and is managed with topical or oral antibiotics rather than by stopping the drug for mild cases.
Option A: Option A is incorrect. The rash is a predictable pharmacologic (on-target) effect, not an allergic reaction, and mild-to-moderate rash is managed without permanent discontinuation.
Option B: Option B is incorrect. It is not an infection. It results from EGFR blockade in the skin; antibiotics like doxycycline are used for their anti-inflammatory effect, not because an infection caused the rash.
Option D: Option D is incorrect. The rash is not caused by drug crystals depositing in skin. It is a biological consequence of EGFR inhibition in epidermal cells.
Option E: Option E is incorrect. EGFR TKIs do not cause the rash by raising blood glucose. The mechanism is on-target EGFR inhibition in the skin.
8. Nilotinib, a BCR-ABL TKI used in CML, must be taken on an empty stomach — no food for at least 2 hours before and 1 hour after each dose. Taking it with a high-fat meal increases the amount absorbed into the blood by roughly 80%. Nilotinib can also lengthen the heart's QT interval (the QTc, an ECG measurement), and this effect grows as the drug level rises. Why is the empty-stomach rule a genuine safety requirement rather than a minor convenience?
A) Food makes nilotinib taste bitter, reducing patient adherence
B) Food sharply raises the blood level of nilotinib, and because its QTc-prolonging effect is concentration-dependent, a food-boosted level can push the patient into a dangerous heart-rhythm range
C) Food neutralizes the drug completely, so a dose taken with food does nothing at all
D) Food causes the drug to be eliminated by the kidneys before it can act
E) Food converts nilotinib into an inactive metabolite in the stomach
ANSWER: B
Rationale:
Option B is correct. Two facts combine to make this a safety rule. First, a high-fat meal increases nilotinib exposure by about 80%, so dosing with food produces a much higher blood concentration than intended. Second, nilotinib's prolongation of the QTc interval is concentration-dependent — the higher the level, the greater the QTc effect. A food-boosted concentration can therefore push the QTc into a range that risks a dangerous ventricular arrhythmia. Strict fasting keeps the concentration predictable and within a safe range. This illustrates a key concept: a food–drug interaction matters most when the drug has a narrow safety margin tied to its blood level.
Option A: Option A is incorrect. The fasting rule is about pharmacokinetics and cardiac safety, not taste or palatability.
Option C: Option C is incorrect. Food does not neutralize nilotinib; it increases absorption. The danger is too much drug, not too little.
Option D: Option D is incorrect. Food does not divert nilotinib to rapid renal elimination. The relevant effect is increased absorption raising the blood level.
Option E: Option E is incorrect. Food does not convert nilotinib to an inactive form in the stomach. It enhances absorption of the active drug.
9. Osimertinib is an EGFR TKI notable for reaching therapeutic levels in the cerebrospinal fluid — the fluid bathing the brain and spinal cord — meaning it crosses into the central nervous system (CNS) far better than older EGFR TKIs. EGFR-mutant lung cancer frequently spreads to the brain. Why is osimertinib's ability to penetrate the CNS clinically important?
A) It allows the drug to be given by injection into the spinal fluid instead of by mouth
B) It means the drug cannot cause any neurologic side effects
C) It lets the drug be used at a much lower dose than other EGFR TKIs
D) It allows osimertinib to treat brain metastases directly, often replacing the need for upfront whole-brain radiation in suitable patients
E) It prevents the cancer from ever developing resistance
ANSWER: D
Rationale:
Option D is correct. Because EGFR-mutant NSCLC has a strong tendency to metastasize to the brain, a drug that reaches therapeutic concentrations in the CNS can attack those brain lesions directly. Osimertinib achieves CNS response rates of roughly 70–80% in patients with brain metastases, which means it can often serve as initial management of CNS disease and spare patients the neurocognitive harms of upfront whole-brain radiation. This is the central clinical payoff of good CNS penetration: the same oral drug controlling systemic disease can also control disease in the brain.
Option A: Option A is incorrect. Good CNS penetration means the oral drug reaches the brain through the bloodstream; it does not imply or require intrathecal (into-the-spinal-fluid) injection.
Option B: Option B is incorrect. CNS penetration does not eliminate neurologic side effects; in fact some CNS-penetrant TKIs in this class can cause CNS effects. Penetration is about reaching brain tumor, not about being side-effect-free.
Option C: Option C is incorrect. CNS penetration is about distribution into the brain, not about allowing a lower systemic dose.
Option E: Option E is incorrect. Resistance can still develop on osimertinib. CNS penetration improves disease control in the brain; it does not make the tumor permanently resistance-proof.
10. Earlier in this set you learned that the T315I gatekeeper mutation locks the drug out of the BCR-ABL1 ATP pocket and defeats imatinib and the second-generation TKIs (dasatinib, nilotinib). A CML patient's mutation testing now returns T315I. Connecting that concept to drug selection, what is the appropriate next step?
A) Switch to a drug specifically able to overcome T315I — ponatinib (designed to fit past the bulky gatekeeper residue) or asciminib (which binds a different site on the enzyme)
B) Simply switch to a different second-generation TKI such as nilotinib, since each one binds differently
C) Increase the imatinib dose, because T315I resistance is overcome at higher concentrations
D) Stop all TKI therapy, because no available drug has activity against T315I
E) Add a second-generation TKI to imatinib, since the combination overcomes T315I
ANSWER: A
Rationale:
Option A is correct. T315I defeats imatinib and all second-generation ATP-competitive TKIs, so the choice must be a drug engineered to get around it. Ponatinib was rationally designed with a structure (a carbon-carbon triple bond linker) that bypasses the steric clash created by the isoleucine substitution, and it has consistent activity against T315I. Asciminib works by binding a completely different pocket on the ABL1 kinase (an allosteric site), so it retains activity against T315I at the appropriate dose. Detecting T315I therefore directs therapy specifically to one of these two agents — the practical clinical consequence of the gatekeeper concept.
Option B: Option B is incorrect. T315I confers cross-resistance to all second-generation TKIs; switching among nilotinib, dasatinib, or bosutinib will fail. Mutation-blind switching is the classic error this testing is meant to prevent.
Option C: Option C is incorrect. T315I is not overcome by raising the imatinib dose; the drug simply cannot occupy the altered pocket regardless of concentration.
Option D: Option D is incorrect. Effective agents do exist — ponatinib and asciminib — so stopping all TKI therapy is wrong.
Option E: Option E is incorrect. Combining imatinib with another second-generation TKI does not overcome T315I, because none of those agents binds the mutated pocket.
11. You learned that the acneiform rash from EGFR TKIs is an on-target effect — the drug blocking EGFR in the skin just as it does in the tumor. A patient develops a moderate rash and worries it means the drug is harming them or not working. Connecting the on-target concept to what it predicts, what can the clinician tell the patient about the significance of the rash?
A) The rash means the drug has stopped reaching the tumor and a dose increase is needed
B) The rash indicates the tumor has become resistant to the drug
C) The rash is unrelated to the drug and should be evaluated as a separate skin disease
D) The rash proves the patient is allergic and the drug must be permanently discontinued
E) Because the rash reflects the drug effectively engaging its EGFR target, a more pronounced rash is actually associated with a better tumor response and improved survival
ANSWER: E
Rationale:
Option E is correct. The rash and the anti-tumor effect spring from the same action — blockade of EGFR. So the appearance and severity of the acneiform rash serve as a visible marker that the drug is hitting its target, and studies show that patients with more pronounced rash tend to have better tumor responses and improved overall survival. This lets the clinician reframe the rash for the patient: it is an expected, even reassuring, sign of drug activity that is managed supportively rather than a reason for alarm. It is a memorable example of an on-target side effect doubling as a positive predictive biomarker.
Option A: Option A is incorrect. The rash signals that the drug is reaching and engaging EGFR, not that it has stopped reaching the tumor.
Option B: Option B is incorrect. The rash is a marker of drug activity, the opposite of resistance.
Option C: Option C is incorrect. The rash is directly caused by the drug's EGFR inhibition in skin; it is not an unrelated dermatologic condition.
Option D: Option D is incorrect. The rash is a predictable on-target pharmacologic effect, not an allergy, and is generally managed without permanent discontinuation.
12. Dasatinib, a BCR-ABL TKI, needs an acidic stomach environment to dissolve before it can be absorbed. A CML patient taking dasatinib is also started on a proton pump inhibitor (PPI, a drug that strongly suppresses stomach acid) for reflux. Connecting the drug's dissolution requirement to this new medication, what is the likely consequence and the better approach?
A) The PPI will increase dasatinib absorption, risking toxicity, so the dasatinib dose should be lowered
B) The PPI has no effect on dasatinib, so the two can be combined freely
C) The PPI raises gastric pH and reduces dasatinib dissolution and absorption, lowering its blood level and risking treatment failure; if acid suppression is truly needed, a shorter-acting H2 blocker given separated in time from dasatinib is preferred
D) The PPI will cause dasatinib to be absorbed too quickly, leading to a dangerous spike in drug level
E) The PPI converts dasatinib into a more potent active metabolite, increasing its effect
ANSWER: C
Rationale:
Option C is correct. Dasatinib requires an acidic environment to dissolve, so a drug that suppresses stomach acid undermines its absorption. A PPI raises gastric pH and reduces dasatinib exposure substantially (on the order of 40–50%), which can drop the level below what is needed to control the leukemia — a setup for treatment failure. The better approach when acid suppression is genuinely necessary is to use a shorter-acting H2-receptor antagonist (an H2 blocker) given separated in time from the dasatinib dose, or an antacid likewise separated by a couple of hours, so the brief drop in acidity does not coincide with dasatinib absorption. This connects a pharmacokinetic property (acid-dependent dissolution) to a concrete prescribing decision.
Option A: Option A is incorrect. The PPI decreases, not increases, dasatinib absorption; the risk is an inadequate level and treatment failure, not toxicity.
Option B: Option B is incorrect. The interaction is clinically significant — reduced absorption — so the combination is not harmless.
Option D: Option D is incorrect. The PPI slows/reduces dissolution rather than speeding absorption; there is no dangerous spike.
Option E: Option E is incorrect. The PPI does not transform dasatinib into a more potent metabolite; it reduces the amount of active drug absorbed.
13. An EGFR-mutant NSCLC patient initially responds to a first-generation EGFR TKI but progresses after about a year. Testing of tumor DNA in the blood (circulating tumor DNA, the fragments of tumor DNA a clinician can sample from a blood draw) reveals a new T790M mutation in EGFR — the most common acquired resistance change to first-generation EGFR TKIs. Connecting the resistance concept to drug selection, what is the appropriate next step?
A) Switch to osimertinib, a later-generation EGFR TKI specifically designed to remain active against the T790M-mutated receptor
B) Switch to an ALK inhibitor such as crizotinib, since the tumor has changed drivers
C) Increase the dose of the current first-generation TKI to overcome T790M
D) Stop targeted therapy permanently because T790M cannot be treated
E) Add a BCR-ABL TKI such as imatinib to the regimen
ANSWER: A
Rationale:
Option A is correct. T790M is a gatekeeper-type change in EGFR that restores the receptor's affinity for ATP and sterically hinders first-generation drugs, exactly analogous to T315I in BCR-ABL1. Osimertinib was purpose-built to bind and inhibit EGFR even when T790M is present (while relatively sparing normal wild-type EGFR), so detecting T790M at progression directs therapy specifically to osimertinib. This is the EGFR-world parallel to the T315I → ponatinib/asciminib logic established earlier: identify the resistance mutation, then choose the agent engineered to defeat it.
Option B: Option B is incorrect. The tumor is still EGFR-driven (now with added T790M); it has not switched to an ALK driver, so an ALK inhibitor is inappropriate.
Option C: Option C is incorrect. T790M is not overcome by raising the first-generation TKI dose; a drug active against the mutant receptor is required.
Option D: Option D is incorrect. T790M is specifically targetable with osimertinib, so abandoning targeted therapy is wrong.
Option E: Option E is incorrect. Imatinib targets BCR-ABL1 in CML and has no role in EGFR-mutant lung cancer.
14. Every BCR-ABL TKI discussed so far (imatinib, dasatinib, nilotinib, ponatinib) works by competing with ATP for the same ATP-binding pocket. Asciminib is different: it is described as a STAMP inhibitor, meaning it binds the myristoyl pocket — a separate site on the ABL1 kinase, away from the ATP pocket. Connecting this distinct binding site to its clinical usefulness, why does asciminib retain activity against mutations that defeat the other drugs?
A) Because asciminib binds DNA rather than the kinase, bypassing kinase mutations entirely
B) Because asciminib binds a different pocket (an allosteric site) than the ATP-competitive drugs, mutations in the ATP pocket that lock those drugs out — including T315I at the appropriate dose — do not block asciminib
C) Because asciminib is given at such high doses that it overwhelms the resistance mutation by sheer concentration
D) Because asciminib destroys the kinase protein rather than inhibiting it
E) Because asciminib prevents the BCR-ABL1 gene from being transcribed in the first place
ANSWER: B
Rationale:
Option B is correct. Resistance mutations such as T315I work by altering the ATP-binding pocket so that ATP-competitive drugs can no longer dock there. Asciminib sidesteps that problem because it binds an entirely different location — the myristoyl pocket — and locks the kinase in an inactive shape through an allosteric mechanism (acting at a site other than the active site). Since its binding does not depend on the ATP pocket, mutations that defeat the ATP-competitive TKIs do not lock asciminib out, and it retains activity against T315I at the appropriate higher dose. This is why a drug with a novel binding site is so valuable in the resistance setting.
Option A: Option A is incorrect. Asciminib binds the kinase protein at the myristoyl pocket; it does not bind DNA.
Option C: Option C is incorrect. Its activity against resistant mutations comes from binding a different site, not from overwhelming the mutation with concentration.
Option D: Option D is incorrect. Asciminib inhibits the kinase by holding it in an inactive conformation; it does not degrade or destroy the protein.
Option E: Option E is incorrect. Asciminib acts on the existing kinase protein, not by blocking transcription of the BCR-ABL1 gene.
15. A patient on an EGFR TKI develops new shortness of breath, dry cough, and low-grade fever a few weeks into therapy, and a CT scan shows diffuse ground-glass opacities in both lungs. This picture suggests interstitial lung disease (ILD, inflammation and scarring of the lung tissue), the most serious class-wide toxicity of EGFR TKIs. Connecting the severity of this toxicity to the right action, what should the clinician do?
A) Continue the TKI unchanged and recheck the CT in three months
B) Continue the TKI but add an inhaled bronchodilator for the symptoms
C) Increase the TKI dose, since worsening lung findings suggest the cancer is progressing and needs more drug
D) Hold the TKI immediately while evaluating, because drug-induced ILD can progress to fatal respiratory failure and delayed interruption increases that risk
E) Switch immediately to a BCR-ABL TKI, which does not affect the lungs
ANSWER: D
Rationale:
Option D is correct. ILD/pneumonitis is the most dangerous class toxicity of EGFR TKIs because it can progress rapidly to life-threatening respiratory failure. When the clinical and imaging picture suggests drug-induced ILD, the TKI must be held immediately while the evaluation (ruling out infection and progression) proceeds, because delaying interruption raises the risk of a fatal outcome; severe cases also require systemic corticosteroids and hospitalization. The high stakes of this toxicity drive an immediate-hold response rather than watchful waiting — the connection between toxicity severity and urgency of action.
Option A: Option A is incorrect. Watchful waiting with an unchanged drug is unsafe when ILD is suspected; the condition can deteriorate quickly.
Option B: Option B is incorrect. A bronchodilator does not address drug-induced ILD, and continuing the offending drug leaves the patient at risk.
Option C: Option C is incorrect. Bilateral ground-glass opacities with these symptoms point toward drug-induced ILD, not simple progression; increasing the dose would worsen the toxicity.
Option E: Option E is incorrect. Reflexively switching to an unrelated BCR-ABL TKI does not treat the lung process, and the immediate priority is to hold the offending drug and evaluate.
16. You have seen that food can raise a TKI's blood level (nilotinib) and that acid suppression can lower one (dasatinib). Now apply the same blood-level reasoning to liver metabolism. Imatinib is broken down by a liver enzyme called CYP3A4. A CML patient on imatinib is started on rifampin for tuberculosis; rifampin strongly induces (ramps up production of) CYP3A4. What is the predicted effect and the appropriate response?
A) Rifampin will block CYP3A4, raising imatinib levels and requiring a dose reduction
B) Rifampin has no metabolic interaction with imatinib, so no change is needed
C) Rifampin will cause imatinib to accumulate to toxic levels, so imatinib should be stopped
D) Rifampin will prevent imatinib absorption from the gut, so imatinib should be given intravenously
E) By inducing CYP3A4, rifampin speeds imatinib breakdown and lowers its level, risking loss of leukemia control; imatinib may need a dose increase with monitoring, or an alternative to rifampin
ANSWER: E
Rationale:
Option E is correct. Inducing CYP3A4 means the liver makes more of the enzyme that metabolizes imatinib, so the drug is cleared faster and its blood level falls — potentially below the threshold needed to sustain the cytogenetic and molecular response. The appropriate response is to anticipate a substantial drop (imatinib exposure can fall by roughly 60–70% with a strong inducer) and either increase the imatinib dose with plasma-level monitoring or, when possible, choose a non-inducing alternative. This bridges the recurring theme of the set: anything that changes a TKI's blood level — food, gastric pH, or enzyme induction — can change whether the drug works or harms.
Option A: Option A is incorrect. Rifampin induces (increases) CYP3A4 rather than blocking it, so induction lowers rather than raises imatinib levels, whereas a CYP3A4 inhibitor would be the agent that raises them.
Option B: Option B is incorrect. The interaction is clinically important — accelerated metabolism and reduced efficacy — so doing nothing risks treatment failure.
Option C: Option C is incorrect. Induction lowers imatinib levels; accumulation to toxic levels is the wrong direction.
Option D: Option D is incorrect. Rifampin acts by speeding hepatic metabolism, not by blocking gut absorption, and switching imatinib to an intravenous route is not the solution (and imatinib is an oral drug).
17. Applying what you learned about ILD, consider an ALK-positive NSCLC patient on an ALK TKI who presents with new dyspnea. The differential includes cancer progression, drug-induced lung inflammation (ILD), and infection. On CT, the finding that most favors drug-induced ILD over tumor progression — and which should prompt holding the drug while evaluating — is which of the following?
A) A single new solid mass enlarging at the site of the original tumor
B) A new fluid collection in the pleural space (pleural effusion) on one side
C) New bilateral, non-segmental ground-glass opacities spread diffusely through both lungs, without a new solid tumor mass
D) Shrinkage of the known tumor with no new findings
E) A localized rib lesion suggesting bone metastasis
ANSWER: C
Rationale:
Option C is correct. Drug-induced ILD characteristically appears as diffuse, bilateral, non-segmental ground-glass opacities (or diffuse alveolar damage) without a new discrete tumor mass — a pattern distinct from the focal enlarging lesion expected with tumor progression. Recognizing this pattern in a TKI-treated patient is exactly what should trigger holding the drug while infection and progression are ruled out, the same immediate-hold principle established earlier. This bridges the toxicity concept into a concrete radiographic discrimination the clinician must make at the bedside.
Option A: Option A is incorrect. A single enlarging solid mass at the original site points toward tumor progression, not drug-induced ILD.
Option B: Option B is incorrect. A unilateral pleural effusion has its own differential (including progression) and is not the hallmark bilateral ground-glass pattern of drug-induced ILD.
Option D: Option D is incorrect. Tumor shrinkage indicates treatment response, not a toxicity needing the drug to be held.
Option E: Option E is incorrect. A focal bone lesion suggests metastatic progression, not drug-induced lung inflammation.
18. You learned with osimertinib that getting a drug into the central nervous system matters because lung cancer often spreads to the brain. Apply that same principle to ALK-positive NSCLC, which has a high rate of brain metastasis. Crizotinib was the first ALK inhibitor but penetrates the CNS very poorly, whereas newer agents such as alectinib and lorlatinib reach high concentrations in the brain. Using the CNS-penetration concept, why are the newer ALK inhibitors generally preferred as first-line therapy?
A) Their strong CNS penetration controls and prevents brain metastases — a major site of failure with crizotinib — in addition to controlling systemic disease, translating into longer progression-free survival
B) They are preferred only because they are cheaper than crizotinib
C) They are preferred because they can be given intravenously rather than by mouth
D) They are preferred because they have no drug interactions, unlike crizotinib
E) They are preferred because they eliminate the need for any molecular testing before treatment
ANSWER: A
Rationale:
Option A is correct. Because ALK-positive NSCLC frequently metastasizes to the brain, and because crizotinib penetrates the CNS poorly, CNS progression became the dominant mode of failure on crizotinib even when systemic disease was controlled. Newer ALK inhibitors such as alectinib and lorlatinib achieve high brain concentrations, so they both treat existing brain metastases and delay their emergence, while also overcoming many crizotinib-resistance mutations — yielding markedly longer progression-free survival as first-line therapy. This is the direct ALK-world application of the CNS-penetration principle first met with osimertinib.
Option B: Option B is incorrect. Preference is driven by superior efficacy and CNS coverage, not by cost (the newer agents are not chosen for being cheaper).
Option C: Option C is incorrect. These ALK inhibitors are oral drugs; the advantage is CNS penetration, not an intravenous route.
Option D: Option D is incorrect. The newer agents still have clinically relevant drug interactions (they are CYP3A4 substrates); freedom from interactions is not the reason for preference.
Option E: Option E is incorrect. Molecular testing to confirm the ALK rearrangement is still required before any ALK inhibitor is used; these drugs do not remove that need.
19. You saw with rifampin that inducing a liver enzyme speeds drug breakdown and lowers levels. Now apply the opposite case. Imatinib not only is metabolized by liver enzymes — it also inhibits (blocks) two of them, CYP2C9 and CYP3A4. Warfarin, a blood thinner whose effect is measured by the INR (a clotting test; higher INR means thinner blood and more bleeding risk), is broken down by CYP2C9. A patient on stable warfarin is started on imatinib. What is the predicted effect?
A) Imatinib will speed warfarin breakdown, lowering the INR and risking clotting
B) By blocking CYP2C9, imatinib slows warfarin breakdown, raising warfarin levels and the INR and increasing bleeding risk, so INR must be monitored closely (or warfarin replaced with low-molecular-weight heparin)
C) Imatinib and warfarin do not interact, because they use unrelated enzymes
D) Imatinib will neutralize warfarin chemically in the bloodstream, abolishing its effect
E) Imatinib will increase warfarin's elimination by the kidneys, lowering its level
ANSWER: B
Rationale:
Option B is correct. When a drug blocks the enzyme that clears another drug, the second drug accumulates. Imatinib inhibits CYP2C9 (and CYP3A4), and warfarin is metabolized by CYP2C9, so adding imatinib slows warfarin's breakdown, raises its level, and pushes the INR up — increasing bleeding risk. The appropriate response is intensified INR monitoring with warfarin dose adjustment, or switching to low-molecular-weight heparin when feasible. This is the inhibition counterpart to the rifampin induction example: induction lowers levels, inhibition raises them, and either can be dangerous with a narrow-margin drug like warfarin.
Option A: Option A is incorrect. Imatinib inhibits rather than induces the relevant enzyme, so the INR rises (bleeding risk), not falls.
Option C: Option C is incorrect. They share CYP2C9 — imatinib inhibits it and warfarin is its substrate — so the interaction is real and clinically important.
Option D: Option D is incorrect. The interaction is metabolic (enzyme inhibition), not direct chemical neutralization in the blood.
Option E: Option E is incorrect. The mechanism is reduced hepatic metabolism, not increased renal elimination; the warfarin level rises rather than falls.
20. A 32-year-old woman is about to start a BCR-ABL TKI for CML. The class of drugs in this module shares two important safety counseling points that apply across BCR-ABL, EGFR, and ALK agents. Drawing those general principles together, which statement is correct?
A) Live attenuated vaccines are encouraged during therapy to boost immunity, and pregnancy is safe on these drugs
B) No contraception is needed because these drugs do not affect a developing fetus
C) These drugs are safe in pregnancy but should be stopped before any vaccination
D) These TKIs can harm a developing fetus (they are teratogenic), so effective contraception is required during therapy; and because they impair immune defenses, live attenuated vaccines are contraindicated while inactivated vaccines such as influenza are appropriate
E) These drugs require no special counseling beyond routine cancer-therapy precautions
ANSWER: D
Rationale:
Option D is correct. Two class-wide safety messages apply across the BCR-ABL, EGFR, and ALK TKIs. First, these agents are teratogenic — capable of causing fetal harm — so women of childbearing potential must use effective contraception during therapy (and for a defined period afterward depending on the specific drug's half-life). Second, because the drugs impair immune surveillance, live attenuated vaccines are contraindicated, whereas inactivated vaccines (such as the annual influenza vaccine) are appropriate and encouraged. Pulling these general principles together is exactly the kind of synthesis the bridge questions ask for.
Option A: Option A is incorrect. The reverse is true: live vaccines are contraindicated and pregnancy is unsafe because of teratogenicity.
Option B: Option B is incorrect. Contraception is required precisely because these drugs can harm a fetus.
Option C: Option C is incorrect. These drugs are not safe in pregnancy, and inactivated vaccines need not be withheld; it is live vaccines that are contraindicated.
Option E: Option E is incorrect. Specific counseling on teratogenicity/contraception and on vaccine type is required; routine precautions alone are insufficient.
21. This set has built one unifying idea: each new generation of TKI was created to solve a specific problem of the generation before it — usually a resistance mutation or poor CNS penetration. Using that framework, which pairing of clinical problem to solution is correct?
A) CML with the T315I gatekeeper mutation is best treated by switching to a different second-generation TKI
B) EGFR-mutant NSCLC with acquired T790M is best treated by raising the first-generation TKI dose
C) ALK-positive NSCLC with brain metastases is better served by a CNS-penetrant agent such as alectinib than by crizotinib, just as CML with T315I is served by ponatinib or asciminib and EGFR-mutant disease with T790M is served by osimertinib
D) ALK-positive NSCLC with brain metastases is best served by crizotinib because it was the first ALK inhibitor approved
E) Resistance mutations are best handled by stopping targeted therapy entirely, since newer generations offer no advantage
ANSWER: C
Rationale:
Option C is correct. It states the unifying framework accurately across all three drug families: when crizotinib fails in the CNS, a CNS-penetrant ALK inhibitor such as alectinib is the answer; when BCR-ABL1 acquires T315I, ponatinib or asciminib is the answer; and when EGFR acquires T790M, osimertinib is the answer. In every case a later-generation agent was engineered to defeat the specific problem (a resistance mutation or poor brain penetration) that limited its predecessor. Recognizing this single pattern lets the clinician reason about a new resistance scenario rather than memorizing isolated facts.
Option A: Option A is incorrect. T315I confers cross-resistance to all second-generation TKIs; switching among them fails. The correct move is ponatinib or asciminib.
Option B: Option B is incorrect. T790M is not overcome by raising the first-generation dose; osimertinib is required.
Option D: Option D is incorrect. Crizotinib penetrates the CNS poorly, so it is not the preferred choice for brain metastases; a CNS-penetrant newer agent is preferred.
Option E: Option E is incorrect. Newer generations specifically restore disease control against these problems, so abandoning targeted therapy is the wrong conclusion.
22. You learned two things in this set: that these TKIs are teratogenic so effective contraception is required, and that a drug which induces CYP3A4 speeds the breakdown of drugs metabolized by that enzyme. Lorlatinib, a third-generation ALK inhibitor, is itself a CYP3A4 inducer. Hormonal contraceptives (such as the combined birth-control pill) are broken down by CYP3A4. Combining these two facts, what is the correct contraceptive counseling for a woman of childbearing potential starting lorlatinib?
A) No contraception is needed because lorlatinib protects against pregnancy
B) A standard combined oral contraceptive pill is fully reliable and is the preferred method
C) Contraception can be stopped once therapy begins, since the drug itself prevents conception
D) Any hormonal method is fine as long as the dose is doubled
E) Because lorlatinib induces CYP3A4 and thereby speeds breakdown of hormonal contraceptives, a hormonal method may fail; a non-hormonal method such as a copper IUD (or another non-hormonal barrier method) is required to reliably prevent a pregnancy that the teratogenic drug could harm
ANSWER: E
Rationale:
Option E is correct. Two established concepts combine here. Lorlatinib is teratogenic, so reliable contraception is mandatory; and as a CYP3A4 inducer it accelerates the metabolism of hormonal contraceptives, reducing their blood levels and reliability. A hormonal method could therefore fail, leaving the patient at risk of a pregnancy the drug could harm. The correct counseling is to use a non-hormonal method — a copper intrauterine device (IUD) or another non-hormonal barrier approach — whose effectiveness does not depend on a drug-metabolized hormone level. This is the capstone synthesis of the set: teratogenicity plus enzyme induction together dictate the contraceptive choice.
Option A: Option A is incorrect. Lorlatinib does not prevent pregnancy; it can harm a fetus, which is exactly why contraception is required.
Option B: Option B is incorrect. A combined oral contraceptive is rendered less reliable by lorlatinib's CYP3A4 induction, so it is not the preferred method.
Option C: Option C is incorrect. Contraception must continue; the drug causes fetal harm rather than preventing conception.
Option D: Option D is incorrect. Simply doubling a hormonal dose is not the recommended, reliable solution; a non-hormonal method is advised because the induction effect is not dependably overcome by dose escalation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.